Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT04268498
Title A Study of Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly-Diagnosed Multiple Myeloma
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Memorial Sloan Kettering Cancer Center

multiple myeloma


Carfilzomib + Dexamethasone + Lenalidomide

Bortezomib + Dexamethasone + Lenalidomide

Carfilzomib + Daratumumab + Dexamethasone + Lenalidomide

Age Groups: senior | adult
Covered Countries USA

No variant requirements are available.